This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates
by Kinjel Shah
EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Kidney Disease
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of chronic kidney disease in adults with and without type-II diabetes.
Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study
by Zacks Equity Research
Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.
Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data
by Kinjel Shah
EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.
AstraZeneca (AZN) Rare Disorder Drug Koselugo Gets EU Nod
by Zacks Equity Research
AstraZeneca's (AZN) Koselugo becomes the first medicine approved in Europe for neurofibromatosis type 1 plexiform neurofibromas.
AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU
by Zacks Equity Research
A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.
Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal
by Kinjel Shah
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $58.35 in the latest trading session, marking a -0.1% move from the prior day.
AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19
by Zacks Equity Research
AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.
The Zacks Analyst Blog Highlights: Salesforce, Shopify, AstraZeneca, Micron and Ecolab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Salesforce, Shopify, AstraZeneca, Micron and Ecolab
Top Research Reports for salesforce, Shopify & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com (CRM), Shopify (SHOP), and AstraZeneca (AZN).
J&J (JNJ) Gets FDA Nod for 10M COVID Vaccines, Discards Many
by Zacks Equity Research
J&J (JNJ) gets authorization for two batches of COVID-19 vaccine doses manufactured at Baltimore facility but the FDA discards several others. Europe and Canada stop the rollout of some batches of the vaccine.
AstraZeneca (AZN) COVID-19 Jab's New Side Effect Stated by EMA
by Zacks Equity Research
The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $56.80 in the latest trading session, marking a +0.98% move from the prior day.
Novartis (NVS) Announces Data on Radioligand Therapy at ASCO
by Zacks Equity Research
Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.
Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved
by Zacks Equity Research
The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up
Novo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment
by Zacks Equity Research
Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.
AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan
by Zacks Equity Research
AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
Lilly's (LLY) Fifth Tirzepatide Study Meets All Key Endpoints
by Zacks Equity Research
Lilly's (LLY) SURPASS-4 study evaluating tirzepatide against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk meets all primary and key secondary endpoints.
Company News for May 20, 2021
by Zacks Equity Research
Companies In The News Are: TGT, AMD, AZN, RETA
BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why
by Zacks Equity Research
BioNTech (BNTX) is riding high on the robust performance of its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod
by Zacks Equity Research
The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.
Emergent (EBS) Issues Plan to Resume Bayview Facility Operation
by Zacks Equity Research
Emergent (EBS) starts to make improvements at its Baview facility in order to meet FDA's standard and resume production of J&J's COVID-19 vaccine.